Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
VS
by Pathway Labs

AI Verdict

These tools are adjacent in their focus on cardiology and AI, but serve different primary functions. Jewel is a wearable cardioverter defibrillator for continuous monitoring and treatment of arrhythmias, prioritizing patient compliance and direct intervention. EchoNext, on the other hand, is an AI-powered diagnostic tool that analyzes standard ECGs to detect hidden structural heart disease, offering non-invasive diagnostic support rather than direct treatment.

Choose Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) if…

Choose Jewel Patch Wearable Cardioverter Defibrillator if you need continuous, discreet, and highly compliant monitoring and treatment for life-threatening arrhythmias in patients at temporary risk of sudden cardiac arrest. Its water-resistant, patch-based design allows for continuous wear, including showering, promoting high patient adherence (median wear time over 23 hours/day). This tool is ideal for patients who require temporary protection and would benefit from a device that integrates seamlessly into their daily lives while providing defibrillation capabilities.

View Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) →

Choose EchoNext if…

Choose EchoNext if you need an AI-powered, non-invasive screening tool to detect hidden structural heart disease from standard ECGs. This tool is particularly well-suited for broad access in various clinical settings, from major hospitals to community practices, to identify patients who warrant further evaluation with cardiac ultrasound. EchoNext can help bridge diagnostic gaps by identifying conditions like heart failure, valve disease, and pulmonary hypertension, even outperforming cardiologists in some instances.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) EchoNext
Pricing Contact vendor Starts at $600/month
Deployment Hardware device with associated mobile application and cloud-based digital health platform. Available through the OpenEvidence clinical decision support platform.
BAA Available Unknown Yes AI-estimated
FDA Status Yes AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) is designed for high patient compliance with a median wear time of over 23 hours/day due to its discreet, water-resistant, patch-based design that allows for continuous wear, including showering. EchoNext, while non-invasive, is a diagnostic tool that analyzes ECGs, which are standard but require a clinical setting for the initial test. Jewel's focus on continuous, patient-friendly wear makes it more usable in a daily life context.

Clinical Value

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)

Jewel P-WCD offers direct therapeutic intervention by detecting and treating life-threatening arrhythmias, with studies demonstrating high safety, compliance, and efficacy in preventing sudden cardiac arrest. EchoNext provides diagnostic support by identifying hidden structural heart disease from ECGs, and while it has shown higher accuracy than cardiologists in studies, it is a screening tool that prompts further investigation rather than providing immediate life-saving treatment.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts, making its cost structure clear to potential customers. Jewel P-WCD's pricing is not publicly available, requiring direct vendor contact, which makes it difficult to assess its value proposition without more information.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating a broader existing integration and scalability for enterprise adoption. It also explicitly states it's designed for broad access, from major hospitals to community practices, and has a BAA in place. Jewel P-WCD is a hardware device with associated digital health platforms that are likely HIPAA compliant and have BAAs, but its deployment is described as a hardware device with an associated mobile application and cloud platform, which suggests a more contained deployment model compared to EchoNext's platform integration.

Innovation

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)

Jewel P-WCD represents a significant innovation in wearable defibrillator technology with its patch-based, water-resistant design and machine learning algorithm for continuous monitoring and treatment, addressing prior issues with patient compliance in traditional WCDs. EchoNext is innovative in its application of AI to standard ECGs for detecting hidden structural heart disease, outperforming cardiologists in diagnostic accuracy. However, the Jewel's ability to provide both continuous monitoring and direct therapeutic intervention in a highly compliant form factor pushes the boundaries of wearable medical devices further.

Support & Docs

Tie

Both tools provide general indications of support. Pathway Labs (EchoNext) offers guided implementation and onboarding, customer testimonials praising their support, and resources like API docs, troubleshooting guides, and GitHub for technical issues. Element Science (Jewel) mentions associated mobile apps and cloud platforms, implying support for these digital components, and their website includes manuals and information on their IDE study. Without more specific details on the breadth and depth of support channels, documentation, and SLAs for both, it's difficult to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) EchoNext
Tool Name Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) EchoNext
Company Element Science, Inc. Pathway Labs
Description The Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) is a water-resistant, patch-based device with a machine learning algorithm for continuous heart monitoring and treatment of life-threatening arrhythmias, designed for high patient compliance. EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features Patch-based wearable cardioverter defibrillator, Water-resistant design for continuous wear, including showering, Machine learning detection algorithm for arrhythmia detection, Continuous heart rhythm monitoring, Detects and treats specific life-threatening arrhythmias, High patient compliance (median wear time over 23 hours/day), Discreet, under-clothing design, Associated Jewel Mobile App for near real-time therapy information to medical team AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support
Categories Cardiology AI, Wearables & Remote Monitoring (RPM) Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics

Videos

Demos, reviews, and walkthroughs featuring Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) and EchoNext.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Jewel is a patch-based wearable device with an associated mobile app and cloud-based digital health platform, suggesting a workflow where data is transmitted to a medical team for near real-time therapy information. EchoNext, on the other hand, integrates through the OpenEvidence clinical decision support platform and analyzes standard 12-lead ECGs, implying it can be incorporated into existing ECG interpretation workflows.
The Jewel P-WCD's machine learning algorithm is designed to detect and treat specific life-threatening arrhythmias, with clinical data showing successful conversion of ventricular tachycardia or fibrillation events and a low rate of inappropriate shocks. EchoNext has demonstrated high accuracy in detecting hidden structural heart disease, achieving an AUROC of 85% in internal tests and 78-80% in external validation, and in studies, it showed higher accuracy (77%) compared to cardiologists at baseline (64%).
Jewel is primarily for cardiology, specifically for patients at risk of sudden cardiac arrest who are not immediate candidates for implantable defibrillator therapy, offering continuous monitoring and treatment. EchoNext is suitable for cardiology, family medicine, hospital medicine, and internal medicine, as it aids in the early detection of hidden structural heart disease from standard ECGs, which can be valuable in broader screening efforts.
The Jewel P-WCD is designed for high patient compliance with continuous wear and a discreet design, suggesting a focus on ease of use for the patient, and its associated mobile app provides streamlined information to the medical team. EchoNext analyzes standard 12-lead ECGs, which are already a familiar diagnostic tool, and its integration into a clinical decision support platform implies it would augment existing interpretation skills rather than requiring extensive new procedural training.
For Jewel, clinical data from a U.S. pivotal trial and an EP Lab Study have been published in the Journal of the American College of Cardiology and Europace, demonstrating its effectiveness and high patient compliance. EchoNext has been validated in internal and external studies across multiple health systems, with findings leading to the initiation of a large cardiovascular AI randomized controlled trial (CACTUS).
The provided information does not explicitly detail specific audit-trail features for either Jewel or EchoNext. Jewel's associated mobile app provides near real-time therapy information to the medical team, which may imply some level of data logging. EchoNext's integration into a clinical decision support platform might leverage the platform's existing audit capabilities, but this is not specified.
AI Tool Finder
AI-powered search. Results may not be comprehensive.